Cybin Inc. (CYBN): Price and Financial Metrics

Cybin Inc. (CYBN): $0.65

-0.02 (-2.93%)

POWR Rating

Component Grades













Add CYBN to Watchlist
Sign Up

Industry: Biotech



in industry

CYBN Stock Price Chart Interactive Chart >

Price chart for CYBN

CYBN Price/Volume Stats

Current price $0.65 52-week high $3.38
Prev. close $0.67 52-week low $0.39
Day low $0.60 Volume 449,200
Day high $0.69 Avg. volume 766,509
50-day MA $0.67 Dividend yield N/A
200-day MA $1.35 Market Cap 106.79M

Cybin Inc. (CYBN) Company Bio

Cybin, Inc. is a biotechnology company that focuses on progressing psychedelic therapeutics by utilizing proprietary drug discovery platforms, drug delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders. It operates through the following segments: Serenity Life and Natures Journey. The Serenity Life segment engages in the research and development of pharmaceutical and nutraceutical psilocybin products. The Natures Journey segment focuses on non-psychedelic medical mushroom nutraceutical products. The company was founded by Paul Glavine, Eric So, and John Kanakis on October 13, 2016 and is headquartered in Toronto, Canada.

CYBN Latest News Stream

Event/Time News Detail
Loading, please wait...

CYBN Latest Social Stream

Loading social stream, please wait...

View Full CYBN Social Stream

Latest CYBN News From Around the Web

Below are the latest news stories about Cybin Inc that investors may wish to consider to help them evaluate CYBN as an investment opportunity.

Cybin Reports Adelia Milestone

This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Cybin (NEO: CYBN) (NYSE American: CYBN ), a biopharmaceutical company focused has announced that subsidiary Adelia Therapeutics Inc. has achieved a milestone outlined in the contribution agreement between Cybin, Cybin Corp., Cybin US Holdings Inc. and previous Adelia shareholders; the milestone was identified as Year 2 Q2 (iii). According to the transaction agreement, 17,239.5 Cybin class B common shares will be issued to Adelia shareholders when relevant milestones have been met; the class B Shares will be exchangeable for common shares in the capital of Cybin at an exchange rate of 10 to 1. Adelia is working on developing medicinal psychedelics ...

Benzinga | February 22, 2022

Psyched: Psilocybin Therapy Effective After One Year, Cybin & Deepak Chopra, Enveric Psilocybin Cancer Study

Psilocybin received yet another confirmation of its beneficial effects in the treatment of major depressive disorder, this time, in the long term. A new Johns Hopkins review study found that the positive effects of just two sessions of psilocybin-assisted psychotherapy can last for over one year in most patients with depression. The movement for psychedelics-positive legislation keeps getting stronger. In Hawaii, a Senator committee approved a bill to study the benefits of psilocybin mushrooms. Public companies in the psychedelics space also came up with substantial milestones. Field Trip (NASDAQ: FTRP ) posted a 330% increase in year-over-year revenue for Q3 , though the company still had over ten times as much net loss as it had revenue, showing the psychedelics space is still a growt...

Benzinga | February 22, 2022

Cybin Announces Additional Adelia Milestone Achievement

TORONTO, February 18, 2022--Cybin Announces Additional Adelia Milestone Achievement

Yahoo | February 18, 2022

Cybin Chopra Foundation Team To Advance Psychedelics In Mental Health

This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Cybin (NYSE American: CYBN ) (NEO: CYBN), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics(TM),” has entered a strategic partnership with The Chopra Foundation , a not-for-profit organization founded by Dr. Deepak Chopra, dedicated to improving health and well-being. Under the collaboration, The Chopra Foundation is working closely with Cybin to support education and awareness about its groundbreaking research to harness the potential of psychedelic therapies in mental health. Emerging research shows the potential for psychedelic-assisted therapy to improve the quality of life for people suffering with mental illnesses...

Benzinga | February 16, 2022

Cybin Turning Psychedelics-to-Therapeutics(TM) Vision Into Reality

This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Cybin (NYSE American: CYBN ) (NEO: CYBN), a life sciences company advancing psychedelic therapeutics for various psychiatric and neurological conditions, is on a mission to revolutionize mental health care. The company has developed key relationships with a network of world-class partners and internationally recognized scientists as it focuses on creating safe and effective therapeutics for patients to address a multitude of mental health issues. “The company is working on turning its Psychedelics to Therapeutics(TM) vision into reality by engineering drug-discovery platforms, innovative drug-delivery systems, novel formulation approaches and treatme...

Benzinga | February 15, 2022

Read More 'CYBN' Stories Here

CYBN Price Returns

1-mo 18.18%
3-mo -28.44%
6-mo -55.78%
1-year -54.23%
3-year N/A
5-year N/A
YTD -45.83%
2021 -19.46%
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7156 seconds.